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A case of hyperhemolytic transfusion reaction attributable to anti-
Fy3 in a 30-year-oldAfricanAmerican woman with a history of sickle
cell disease is reported. The patient was admitted for vaso-occlusive
sickle cell crisis and received 4 units of packed RBCs secondary to
worsening symptomatic anemia (Hb 5.0 g/dL). On admission, the
patient’s antibody screen and identification showed anti-V and anti-
E, and her antibody history included anti-E, -C, -Jkb, -N, -V, -S, -Sla, and a
cold agglutinin with possible anti-I specificity. A DAT performed on
her RBCs was negative.RBC units that lacked E,C,Jkb,N,V,and S were
transfused. Posttransfusion Hb was 8.9 g/dL. On day 10 she
developed a fever of 103°F, and on day 11 her Hb decreased to 6.4
g/dL. She complained of severe back pain and dark urine. In
addition, she became hypertensive, tachycardic, and jaundiced. The
DAT indicated the presence of IgG on the patient’s RBCs. Anti-Fy3
was identified in the serum and eluate. During the next 24 hours,her
Hb decreased to 2.4 g/dL. The LDH level was 1687 U/L, and her
reticulocyte count was 2.6%. A delayed hemolytic transfusion
reaction with hyperhemolysis secondary to anti-Fy3 was suspected
and was successfully treated with IVIG and high-dose prednisone.
To the best of our knowledge, this is the first published case of
hyperhemolysis in sickle cell disease attributable to anti-Fy3.
Immunohematology 2008:24:45–51.
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Delayed hemolytic transfusion reaction with
hyperhemolysis (DHTR-H) is a serious complication of
transfusion and alloimmunization that has been
reported especially in patients with sickle cell disease.
This condition is characterized by destruction of both
donor and recipient RBCs and is associated with
reticulocytopenia. This syndrome commonly occurs
after an anamnestic response to a donor RBC antigen or
secondary to the formation of new alloantibodies.
Transfusion of more blood products can exacerbate
hemolysis, and it is usually recommended that trans-
fusions be withheld. Although the exact mechanisms
behind hyperhemolysis are not clear, bystander
hemolysis has been suggested as the possible
pathogenesis of this condition.1–5 Treatment with
IVIG and steroids in severe cases of DHTR-H may be
lifesaving.4,6–8 Anti-Fy3 is an uncommon antibody that
has been described in Fy(a–b–) Caucasians and rarely in
African Americans; it is associated with at least one
report of an acute hemolytic transfusion reaction.9
Although cases of hyperhemolysis syndrome have been
described in the literature, none have been associated
with anti-Fy3. This report describes a case of DHTR-H
attributable to anti-Fy3 in an African American patient
with sickle cell disease (SCD).
Case Report
A 30-year-old African American woman with a
history of sickle cell anemia (HbS 83.8%, HbF 11.7%,
HbA2 4.5%),hepatitis C secondary to blood transfusion,
deep venous thrombosis treated with Coumadin
therapy,and previous episodes of acute sickle cell crisis
was admitted to our hospital with complaints of fever;
shortness of breath; and chest, neck, and back pain
which were unresolved with her usual home
medications. At the time of admission, the patient’s Hb
was 6.6 g/dL, Hct 20.1%, reticulocyte count 12.9%
(corrected,5.8%),and total bilirubin 2.5 mg/dL (indirect
bilirubin, 1.7 mg/dL). Blood cultures were positive for
Enterobacter, Klebsiella, and yeast (not Candida
albicans). Despite aggressive hydration and initiation
of antibiotic therapy, the patient’s clinical status con-
tinued to deteriorate. Secondary to worsening anemia
with a Hb of 5.0 g/dL, the patient was transfused with 4
units of leukocyte-reduced packed RBCs on hospital
days 1 and 2. The patient’s RBCs typed as group O,D+,
C–, E–, c+, e+; M+, N–, S–, s+; P1+; K–; Fy(a–b–); and
Jk(a+b–). The patient had a previous history of multiple
alloantibodies including anti-E, -C, -Jkb, -N, -V, -S, and -Sla
and a cold agglutinin with possible anti-I specificity. Of
the 4 units issued, 3 units were C–, E–, K–, Fy(a–b–),
Hyperhemolytic transfusion
reaction attributable to anti-Fy3 in
a patient with sickle cell disease
M.A. REYES AND O.C. ILLOH
C A S E R E P O R T
46 I M M U N O H E M A T O L O G Y, VO L U M E 2 4 , N U M B E R 2 , 2 0 0 8
Jk(b–), S–, and N–. Because of the difficulty of finding
phenotypically matched RBCs for the patient, and the
urgency with which it was needed, 1 unit that was C–,
E–,K–,Fy(a–b+), Jk(b–), S–, and N– was also issued. The
patient’s Hb increased to 8.9 g/dL, and her clinical
symptoms improved.
On hospital day 10, she developed a fever of 103°F
without accompanying symptoms, and blood cultures
were negative. By hospital day 11,her Hb decreased to
6.4 g/dL, and she complained of severe back pain and
dark urine. In addition she became hypertensive,
tachycardic, and jaundiced. The DAT performed on her
RBCs was now positive with anti-IgG and negative with
anti-C3. As there was clinical suspicion of a delayed
hemolytic transfusion reaction, a blood bank inves-
tigation was initiated, and further transfusion was
withheld. The initial work-up was suggestive of anti-Fy3.
This was confirmed by the reference laboratory at Gulf
Coast Regional Blood Center in Houston,Texas. Over
the course of 24 hours, the patient’s Hb continued to
decrease, reaching a nadir of 2.4 g/dL. Her LDH level
was 1687 U/L, total bilirubin was 2.7 mg/dL (indirect
bilirubin, 1.4 mg/dL), and reticulocyte count was 2.6%
(corrected, 0.4%). Haptoglobin measurement was not
done. At this point DHTR-H was suspected. Her clinical
condition continued to deteriorate, and she was started
on high-dose prednisone (60 mg/day) and IVIG (400
mg/kg per day) for a treatment course of 5 days. On
hospital day 13 the patient developed clinical symptoms
of hemodynamic compromise including shortness of
breath, tachypnea, systolic ejection murmur, and severe
pallor. Her Hb was 2.6 g/dL. The decision was made to
transfuse 1 unit of phenotypically matched (C–, E–, K–,
Fy(a–b–), Jk(b–), S–, and N–), leukocyte-reduced packed
RBCs and monitor closely for additional signs of
hemolysis. Her Hb improved to 3.6 g/dL, and pred-
nisone and IVIG treatment were continued. Her LDH
level decreased during the ensuing days, and
reticulocyte count increased to 6.3% (corrected, 1.5%).
Her Hb continued to improve (up to 5.6 g/dL) and
remained stable until hospital day 30 when the patient
had an episode of epistaxis because of trauma from her
nasal canula and baseline anticoagulation therapy for
her history of deep vein thrombosis. Her Hb dropped to
2.6 g/dL. She was transfused with 1 unit of pheno-
typically matched (C–, E–, K–, Fy[a–b–], Jk[b–],
S–, and N–), leukocyte-reduced packed RBCs. After
transfusion her Hb increased to 3.3 g/dL and remained
stable for the next day. Because her LDH level was 733
U/L and total bilirubin was 6.4 mg/dL with an indirect
component of 3.4 mg/dL, hemolysis was again sus-
pected. Her reticulocyte count was 15.1% (corrected,
2.6%) and haptoglobin was less than 6 mg/dL. The
patient was restarted on high-dose prednisone (500
mg/day) and IVIG (400 mg/kg/day) immediately for a
duration of 5 days. Her hemoglobin and clinical symp-
toms steadily improved, with no further evidence of
hemolytic episodes. She was discharged with a Hb of
6.0 g/dL on hospital day 43. The hemoglobin and
reticulocyte counts through her hospital course are
shown in Figures 1 and 2.
Materials and Methods
ABO and D testing were performed by standard tube
testing using commercial reagents according to the
manufacturer’s protocol (Immucor, Inc., Norcross,GA).
Antibody detection and identification tests were
performed using gel methodology (ID-MTS Gel Test,
Ortho-Clinical Diagnostics, Raritan, NJ). The patient’s
serum was tested against panels of commercial reagent
RBCs (Ortho-Clinical Diagnostics) to determine anti-
body specificities. The DAT was performed with
polyspecific antihuman globulin and monospecific anti-
IgG and anti-C3d reagents (Gamma Biologicals, Inc.,
Houston,TX). The eluate, prepared by an acid elution
method (ELU-KIT II,Gamma Biologicals, Inc.) was tested
against panels of commercially available reagent RBCs
(Ortho-Clinical Diagnostics). The patient’s serum was
also tested against ficin-treated RBCs (Ortho-Clinical
Diagnostics). The patient’s RBCs were typed for Rh,Kell,
MNS, Lewis, Duffy, and Kidd major antigens using
specific antisera according to the manufacturer’s
protocol (Immucor, Inc.,Norcross,GA).
Results
Pretransfusion, the patient typed as group O, D+
with a positive antibody screen. Anti-E and anti-V were
identified in the sample. Historic records showed that
she had multiple alloantibodies (anti-E, -C, -Jkb, -N, -V, -S,
-I,and -Sla). The phenotype on record was D+,C–,E–,c+,
e+;M+,N–, S–, s+; P1+;K–; Fy(a–b–); and Jk(a+b–). The
posttransfusion sample showed a positive antibody
screen. The patient’s serum was reactive with all Fy(a+)
and Fy(b+) RBCs and only nonreactive with a donor
RBC that matched her phenotype and was also Fy(a–
b–). The serum sample showed reactivity after ficin
treatment. The presence of anti-Fy3 was confirmed by
the reference laboratory at Gulf Coast Regional Blood
Center in Houston,Texas. The DAT was 3+ with poly-
specific reagent, 3+ with anti-IgG, and negative with
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Fig. 1. Patient hemoglobin levels throughout hospital admission. PRBCs = packed RBCs.
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anti-C3d. The eluate showed reactivity with most donor
RBCs except those that were Fy(a–b–). The phenotypes
of the transfused units are as described earlier.
Discussion
This report describes a case of DHTR-H. In this case,
a new antibody (anti-Fy3) was detected in the patient’s
serum on repeat testing. To our knowledge, no case of
DHTR-H attributable to the formation of anti-Fy3
alloantibody has been previously published.
Patients with SCD require frequent RBC transfusions
or RBC exchange. Alloimmunization to RBC antigens
occurs in anywhere from 18 to 47 percent of chronically
transfused patients with SCD.10–12 The formation of
multiple antibodies presents a challenge in finding
compatible blood units for these patients,and it is often
not possible to provide completely phenotype-matched
units and therefore prevent further antibody formation.
Delayed hemolytic transfusion reaction (DHTR) is a
common complication of alloimmunization. This
reaction occurs 3 to 14 days after transfusion and
presents with anemia, fever, and a positive DAT. On
occasion,hyperhemolysis syndrome may occur as a life-
threatening manifestation of DHTR. Hyperhemolysis
syndrome is characterized by a drop in posttransfusion
hemoglobin below pretransfusion levels, elevated LDH
level and bilirubin,fever,pain,and hemoglobinuria. One
unique finding in patients with this condition is
reticulocytopenia. On many occasions the presenting
symptoms of DHTR-H resemble manifestations of sickle
cell crises.4,13–16 Therefore,a DHTR must be kept in the
differential diagnoses of all recently transfused patients
with SCD with vaso-occlusive crises.4 Delay in diagnosis
may lead to inappropriate management and increased
morbidity or mortality for these patients. In our case,
sickle cell crisis was ruled out, and the presence of
a newly detected antibody, combined with a severe
drop in hemoglobin levels, supported the diagnosis of
DHTR-H.
The mechanism of hyperhemolysis is not com-
pletely understood. Multiple studies have supported the
fact that autologous RBCs are destroyed, in addition to
destruction of transfused RBCs. A bystander hemolysis
theory has been proposed.1–5 Mechanisms by which
this proposed bystander hemolysis occurs include
epitope spreading and the defective regulation of the
formation of the complement membrane attack com-
plex in sickle RBCs.17 Sickle RBCs more often expose
cryptic antigens and therefore have a high level of
surface IgG. This makes the RBCs more susceptible to
destruction by active macrophages.18,19 Of interest,
cases of hyperhemolysis have been reported in thalas-
semia patients after transfusion of RBC units.20 This
suggests that the presence of sickle RBCs alone is not
enough to fully explain the hyperhemolysis phenom-
enon. In close to 50 percent of cases of hyperhemolysis,
no new antibody is identified. Garratty21 has proposed
that in the absence of alloantibodies, other antibodies
(including HLA antibodies) reacting with foreign
proteins may cause complement activation and RBC
hemolysis.
Typically in anemia caused by hemolysis, compen-
satory reticulocytosis is observed. However,many cases
of DHTR-H show inappropriately low reticulocyte
counts. The suggested mechanisms of reticulocytopenia
include transfusion suppression of erythropoiesis,
accelerated destruction of reticulocytes, and decreased
levels of erythropoietin secondary to renal damage.2,10
Previous case reports have shown an increase in
reticulocyte production after the administration of IVIG
or steroid treatment.6,8 This supports the theory of
antibody-mediated accelerated destruction of reticu-
locytes and hyperactivity of macrophages. In our
patient, a drop in the reticulocyte count was observed
despite worsening anemia. An increase in the reticulo-
cyte count was observed only after treatment with IVIG
and steroids commenced.
In contrast to the DAT in DHTR without hyperhemo-
lysis, the DAT with hyperhemolytic syndrome is most
often negative, even in the presence of a new antibody.
In a study byTalano et al.,4 patient RBCs in only two of
nine episodes of DHTR-H were positive in the DAT.
These were both associated with new antibodies (warm
autoantibody and anti-E). The negative DAT can be
explained by the hemolysis of transfused RBCs. Our
patient’s RBCs were negative in the DAT before
transfusion,but at the time of the DHTR-H,the DAT was
positive and anti-Fy3 was eluted from RBCs. However,
the DAT was not repeated when her hemoglobin
dropped further. The DAT remained positive even after
the second episode of hyperhemolysis that occurred 3
to 4 weeks later with a negative eluate. Our findings and
the results of others show that the DAT cannot not be
used alone to diagnose DHTR-H.
Anti-Fy3 has been reported to cause both acute and
delayed hemolytic transfusion reactions.9 Several RBC
antibodies have been implicated as a cause of DHTR-H,
but there are no published reports of anti-Fy3 as a cause
of such reactions. This antibody has been described in
individuals with the Fy(a–b–) phenotype, but it very
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rarely occurs in African Americans. Anti-Fy3 was first
described in a CaucasianAustralian woman whose RBCs
were typed as Fy(a–b–). This antibody reacted with all
RBCs that were Fy(a+b–), Fy(a–b+), and Fy(a+b+).
Unlike anti-Fya and anti-Fyb, anti-Fy3 reacted with
enzyme-treated RBCs. Considering that the Fy(a–b–)
phenotype is prevalent in theWest African and African
American populations, one would expect that anti-Fy3
would be a commonly encountered antibody. However,
anti-Fy3 is rarely encountered,and the majority of cases
have been reported in Caucasians. The molecular
mechanisms behind the Fy(a–b–) phenotype in West
African and Caucasian individuals differ. It is believed
that most Africans are homozygous for an FYB allele
with a point mutation in the promoter region of the
gene that prevents expression of the Duffy antigens on
RBCs.22 However, it has been shown that Fyb is
expressed on tissue cells of these same individuals,
particularly the endothelial cells of postcapillary venules
and Purkinje cells of the cerebellum.23 Therefore, they
are prevented from recognizing Fyb as foreign and from
forming anti-Fyb or anti-Fy3. In Caucasians, it has been
found that the Fy(a–b–) phenotype is the result of a
deletion in the FY genes,and therefore there is a lack of
expression of Duffy antigens on their RBCs and tissue
cells.24 These individuals are capable of forming
antibodies to all of the Duffy antigens, including Fy3.
Although this genetic mechanism is known to be found
mostly in Caucasians, it has been proposed that both
genetic mechanisms exist in theAfrican population. Our
patient is African American and therefore would not
have been expected to make this antibody. Genotyping
studies could not be performed, but it is proposed that
her Fy(a–b–) phenotype is the result of a deletion in FY
genes rather than a defect in the FY promoter. When
one is looking for phenotypically matched RBCs for
AfricanAmerican patients with the Fy(a–b–) phenotype,
often the Fy(b–) requirement will be omitted to find
units more quickly and because of the improbability of
anti-Fyb formation in these patients. However, in our
patient, giving a Fy(b+) RBC unit likely contributed to
the initiation of DHTR-H.
Interestingly, this patient also had a history of anti-
Sla, which had been identified by another hospital
approximately 10 years earlier. Anti-Sla and anti-Fy3 can
be difficult to distinguish serologically,and RBCs that are
Fy(a–b–) also tend to be Sl(a–). However,whereas anti-
Sla reactivity is depressed with ficin treatment of RBCs,
anti-Fy3 activity is unaffected by enzyme treatment. This
can be an important distinguishing feature when
differentiating between these antibodies. In our patient,
our reference laboratory (Gulf Coast Regional Blood
Center, Houston, TX) did not identify anti-Sla after
multiple and extensive evaluations.
In patients with DHTR-H,transfusion of more blood
may exacerbate hemolysis. Therefore the transfusion of
RBCs is discouraged unless severe, life-threatening
anemia occurs. In our patient, transfusions were with-
held until the patient developed severe, symptomatic
anemia. She appeared to have responded to IVIG and
steroid treatment with an increasing hemoglobin and
reticulocyte count. However,after a second transfusion,
hyperhemolysis again occurred. Many studies have
reported success with high-dose IVIG and cortico-
steroids, either alone to prevent hemolysis or in
conjunction with RBC transfusions.6,8 How these drugs
help reduce hemolysis is not clear, but some of the
proposed mechanisms include (1) IVIG prevention of
contact-mediated lysis of the RBCs by blocking the
adhesion of sickle cells, reticulocytes,and macrophages,
and (2) IVIG and steroid suppression of hyperactive
macrophages.8 Additional trials and studies are needed
to further define the role of these drugs in this
condition. Although transfusion precipitates most cases
of hyperhemolysis in patients with SCD,there have been
reports of this condition occurring in patients with
uncomplicated acute painful episodes.25 It is possible
the patient’s underlying SCD and acute painful crisis,
even without transfusion,could have contributed to the
hyperhemolytic crisis.
Whether this reaction will occur again in patients
who have had one episode of DHTR-H is not clear. Our
patient seems to be one in whom DHTR-H will very
likely recur. This is despite attempts to provide blood
that matched her complete phenotype. Other reports
have also shown that giving phenotypically matched
blood did not prevent the occurrence of DHTR-H in
some patients.3,4,10 Since this episode, this patient has
presented to the hospital multiple times but has not
been transfused and has maintained baseline Hb of 5 to
6 g/dL.
Conclusion
In conclusion,this is a report of DHTR-H attributable
to anti-Fy3 in an African American woman with SCD.
Anti-Fy3, although rare in African Americans and West
Africans, can be associated with hyper-hemolysis. This
report shows that hyperhemolysis is a serious complica-
tion that should be sought for early and that providing
phenotypically matched units will not always prevent
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DHTR-H from occurring. Withholding trans-fusions and
initiating treatment with IVIG and steroids may be
lifesaving. The complete pathogenesis of this condition
and other treatment options available continue to be
explored.
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